Screener
Beam Therapeutics BEAM EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Beam Therapeutics’s reported figures.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
FAQ
- What is Beam Therapeutics's EBITDA?
- Beam Therapeutics (BEAM) reported EBITDA of -$101.61M in Q1 2026.
- How has Beam Therapeutics's EBITDA changed year-over-year?
- Beam Therapeutics's EBITDA increased by 10.7% year-over-year, from -$113.76M to -$101.61M.
- What is the long-term trend for Beam Therapeutics's EBITDA?
- Over 3 years (2021 to 2025), Beam Therapeutics's EBITDA has grown at a -2.1% compound annual growth rate (CAGR), from -$385.01M to -$361.4M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Beam Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude